Kornimate/medical-research-clean huggingface dataset:
hot water immersion therapy for mental health

Conditions: Anxiety Disorders; Depression; Post-traumatic Stress Disorder; Heat; Water Immersion

Summary: in 2016, it was estimated that nearly 1 billion people worldwide were affected by a mental or addictive disorder, and were associated with considerable excess mortality. acute heat therapy sessions (e.g. whole-body heating or foot immersions) have been shown to improve symptoms in individuals diagnosed with common mental health illness such as major depressive disorders and reduce anxiety. this study will assess the impact of an at-home 8-week lower-limb immersion in hot water on symptom severity in patients diagnosed with major depressive disorder, generalized anxiety disorder, and ptsd.


Eligibility criteria:
inclusion criteria: * over 18 years of age * diagnosed with depression, anxiety, or post-traumatic stress disorder * internet access (e.g. via smartphone, computer) * currently engaging in mental health treatment exclusion criteria: * free of any mental health disorder * not engaging in regular mental health treatment * diagnosed with other psychiatric disorders (e.g. schizophrenia, bipolar disorder, panic disorder)
trial to assess efficacy of a chimeric skin in patients with epidermolysys bullosa

Conditions: EPIDERMOLYSIS BULLOSA

Summary: a phase ii, comparative, open label, prospective, multicentre clinical trial where each patient will undergo two procedures; implant of a patch of cultured chimeric skin (experimental therapy) in a half of the skin lesion and an occlusive non-adherent dressing (control) in the other half for 12 months of follow-up in two spanish centres.

reconstruction of interdigital commisures in patients with severe skin syndactyly using laminar grafts that will be uniformly and systematically taken with an electrical or compressed air dermatome on an aseptic area and with the same extent and depth in microns in all patients. immediately after the surgical procedure, a patch of cultured chimeric skin (experimental therapy) will be implanted in a half of the skin defect of the patient, and an occlusive non - adherent dressing (control) will be implanted in the other half. patients will initially be followed up every two days until epithelisation occurs (approximately 21 days after surgery) and at 3,8,and 12 months of follow-up.

Eligibility criteria:
inclusion criteria: * patients of both sexes over 28 days of age. * patients with recessive dystrophic epidermolysis bullosa diagnosed by clinical and historical criteria with severe skin syndactyly in whom reconstructive surgery is indicated. * patients whose legal guardians have given written informed consent for participation in the study before any study procedure is performed. * patients aged ≥ 12 years who have given written informed consent for participation in the study before any study procedure is performed. exclusion criteria: * women of childbearing age not using effective contraceptive methods (oral contraception) * pregnant or nursing women * documented or suspected hypersensitivity to any of the therapeutic agents included in the study, including anaesthetic drugs. * patients with a history of malignant tumor in the past 5 years * patients with a diagnosis of active tuberculosis at the time of recruitment * patients with prior positive markers for any of the following pathogens: hepatitis b and c, hiv-1 and hiv-2 * patients with a history of clinically relevant hepatic, gastrointestinal, haematological, pulmonary, or neurological disease no directly related to epidermolysis bullosa. * any other medical condition which, in the investigator´s judgment, might interfere with optimal participation in the study or involve a significant risk for the patient. * alcoholism, drug addiction, psychiatric disorders, or other factors present in legal guardians which,in the investigator´s judgment may complicate patient participation in the study.
"electro acupuncture in the treatment and management of chemotherapy induced peripheral neuropathy"

Conditions: Breast Cancer

Summary: to evaluate the effectiveness of electro acupuncture (ea) for treatment of persistent painful cipn symptoms in patients with stages 1-3 breast cancer treated with docetaxel chemotherapy 6 months prior

a double blind prospective randomized controlled pilot study with cross over. to assess the effectiveness of ea in improving pain and function for chronic chemotherapy induced peripheral neuropathy (cipn) 30 participants will be recruited 6 months post-completion of chemotherapy. fifteen participants will be randomized to the true ea group and 15 to the sham ea group. those participants randomized to the sham group will cross over to receive true ea after the trial is complete. treatment consists of ea or sham ea 1 x per week x 6 weeks. re-assessment visits occur after the 6 week intervention and again 2 months post trial. each assessment visit quantifies the sensory experience of cipn at that moment in time using quantitative sensory testing (qst) which includes; thermal detection and thermal pain thresholds, light touch detection using nylon monofilament hairs (semmes weinstein monofilaments (swmf)), static 2-point discrimination, pressure algometry and vibration thresholds. patient reported outcome measures including the disabilities of the arm, shoulder and hand (dash), lower extremity functional score (lefs), the self report leeds assessment of neuropathic signs and symptoms (s-lanss) pain questionaire will also be used.

Eligibility criteria:
inclusion criteria: * any patient diagnosed with stage 1-3 breast cancer who has finished chemotherapy 6 months prior and has residual cipn symptoms graded as a 3/10 or higher on the numeric rating pain scale. exclusion criteria: * patients who have co-morbid conditions that cause peripheral neuropathic symptoms * patients with heart valve replacements * patients on prophylactic antibiotics * patients with severe coagulopathy * patients who did not receive regular taxane therapy

Keywords: electroacupuncture neuropathic pain chemotherapy induced peripheral neuropathy
contrast enhanced ultrasound of carotid plaque in acute ischemic stroke

Conditions: Cerebral Infarction

Summary: this is a biomedical, single-center, and prospective study of a consecutive patients cohort in acute ischemic stroke with carotid plaque.

the main objective of this study is to evaluate the prevalence of the contrast taking carotid plaques in these acute ischemic strokes. the secondary objectives are: * to determine the clinical, sonographic, ct scanner and mri characteristics of patients in constituted acute cerebral ischemia with carotid atherosclerotic plaque taking contrast to the doppler ultrasound. * to explore of the plaque contrast enhancement at 6 months (new injection).

Eligibility criteria:
inclusion criteria: * all patients aged at least 18 years hospitalized with ischemic stroke signs in the carotid territory, objectified on brain mri with positive dwi. * carotid plaque \> 2.5 mm thickness in the ipsilateral carotid territory to the aic, low echogenicity (type 1, 2, 3, and 4a of the classification geroulakos) measured by the assessment "gsm" (median gray level). * free and informed consent patient or his representative for contrast injection microbubble. * affiliated to health insurance. exclusion criteria: * severe cerebral infarction with nihss\> 25 * no-indications to the contrast medium injection * recent myocardial infarction, unstable angina. * heart failure stage iii / iv new york heart association. * cardiac shunt left-right, respiratory distress. * allergy to albumin or contrast agents. * carotid plaques and hyperechoic calcified (however these plaques will be counted to determine their prevalence in acute aic). * carotid dissection
effect of revival soy on fibromyalgia pain

Conditions: Fibromyalgia

Summary: fibromyalgia is characterized by widespread pain that can lead to significant patient dysfunction and economic burden to society. the management of patients with fibromyalgia is difficult and no single treatment modality has been successful. we propose to study the effect of dietary soy supplement on quality of life associated with fibromyalgia.

fibromyalgia syndrome is a chronic, generalized pain syndrome that affects the musculoskeletal system (1). this syndrome is typically diagnosed in patients who experience generalized musculoskeletal pain and have excessive tenderness in at least 11 of 18 specific points (2). although the primary cause of fibromyalgia syndrome is unclear, a growing body of evidence indicates that the widespread pain associated with this syndrome is due to abnormalities in the central nervous system. therefore, drug therapy for fibromyalgia syndrome is most often aimed at the central nervous system and includes tricyclic antidepressants, selective serotonin reuptake inhibitors, dual serotonin and norepinephrine reuptake inhibitors, analgesics, and anticonvulsants (1). in addition to medical therapies, complementary and alternative medicine therapies have been used to treat fibromyalgia syndrome symptoms (3). soy is a widely used dietary supplement that has not been previously tested for treating fibromyalgia syndrome.

Eligibility criteria:
inclusion criteria: * women and men age 18 - 76 * able to understand and sign a consent form * able to participate fully in all aspects of the study * currently participating in mayo clinic's fibromyalgia treatment program exclusion criteria: * pregnant or lactating women * allergy to soy or other study product ingredients * diagnosis of bipolar disorder, schizophrenia or dementia * diagnosis of diabetes mellitus or inflammatory bowel disease * presently on soy product or use of soy within the last 30 days

Keywords: fibromyalgia dietary supplements rheumatologic diseases complementary and alternative medicine
exploratory study of coronary flow reserve measurements, a non-invasive method for coronary function measurements

Conditions: Atherosclerosis; Inflammatory Activity in Coronary Arteries

Summary: the aim of this study is to investigate whether the non-invasive ultrasound method for assessment of coronary blood flow, transthoracic doppler echocardiography-coronary flow reserve (ttde-cfr), can be used to measure drug effects.


Eligibility criteria:
inclusion criteria: * males aged 45-75 years or females aged 60-75 years inclusive * carotid and/or femoral atherosclerotic plaque, as assessed by carotid ultrasound examination within the last 5 years * abnormal concentrations of lipids or lipoproteins in the blood * provision of signed informed consent exclusion criteria: * treatment with statins or other lipid-lowering drugs, e.g. fibrates, nicotinic acid, cholesterol absorption inhibitor, within the last 6 months before randomisation * current smoking or snuff tobacco use * major cv event (myocardial infarction (mi), stroke/ transitory ischemic attack (tia), acute coronary syndrome (acs), revascularisation) within the last 6 months before randomisation * symptomatic carotid stenosis, atrioventricular (av) block, qt-prolongation, atrial fibrillation, sinus node disease (such as sick sinus syndrome or symptomatic bradycardia), chronic obstructive pulmonary disease (copd) or asthma

Keywords: ttde-cfr coronary artery function cardiovascular biomarkers rosuvastatin crestor
tympanoseal (tympanic membrane device) clinical study

Conditions: Tympanic Membrane Perforation

Summary: the purpose of this investigational study is to assess the ability of tympanoseal (sodium/calcium alginate), an investigational device, to act as a scaffold during healing of the tympanic membrane. tympanoseal is intended for use following removal or extrusion of indwelling tympanostomy tubes or traumatic injury of the tympanic membrane.

this study will provide data on the safety and the ability of sodium/calcium alginate gels to act as a scaffold capable of occluding a tympanic membrane perforation over the duration of complete healing. tympanoseal could be used in cases where cartilage or fat graft tympanoplasty would be indicated.

Eligibility criteria:
inclusion criteria: * male or female patients over 2 years of age at enrollment * documentation of a retained tympanostomy tube or persistent perforation less that 5 mm. * written informed consent (and assent when applicable) obtained from subject or subject's legal guardian and ability for subject to comply with the requirements of the study exclusion criteria: * active otorrhea or otitis media * history of cholesteatoma * perforations on the edge of the tympanic membrane * presence of a condition or abnormality that in the opinion of the investigator would compromise the safety of the patient or the quality of the data * subject is taking systemic corticosteroids * subject requires continued use of any type of topical otic medication
allopurinol in chronic heart failure

Conditions: Chronic Heart Failure; Hyperuricemia

Summary: the purpose of this study is to discover whether the inhibition of the xanthine oxidase with allopurinol leads to a reduction of the production of oxygen free radicals in patients with chf and thereby improves characteristics of oxydative metabolism, peripheral blood flow, immune function and functional status.


Eligibility criteria:
inclusion criteria: * the patient is a male and at least 21 years of age. * the patient has clinical evidence of heart failure: a) reduced ejection fraction (≤40%) or cardiomegaly on cxr or left ventricular impairment on echocardiography (lvedd ≥60mm), b) stable clinical condition and medication for at least 1 month prior to the study. * no history of unstable angina, myocardial infarction or stroke within 3 months prior to the study. * the patient is receiving full conventional medical therapy for heart failure (ace inhibitor or angiotensin ii blocker, diuretics etc.). * the patient is willing and capable of complying with the requirements of this protocol. * the patient has provided written informed consent . exclusion criteria: * the patient has any life-threatening disease, other than heart failure (including patients with known, or suspected, myocarditis or with automatic implantable cardioverter/defibrillators). * the patient has an active malignancy of any type, or history of a malignancy (patients who have a history of basal cell carcinoma that has been surgically removed are acceptable). patients with a history of other malignancies that have been surgically removed and who have no evidence of recurrence for at least five years prior to study enrolment are also acceptable. * the patient has had a heart transplant. * the patient has severe renal disease (s-creatinine \>300 μmol/l), severe liver disease (asat or alat \> 3 times of upper limit of normal range), rheumatoid arthritis, or complains of gout. * the patients has received allopurinol therapy previously or if he is known to suffer from gout (acutely or chronically). * the patient has an exercise capacity of \> 20 ml/kg/min (treadmill, bruce protocol) or is in functional nyha class i.
malnutrition associated with complications after ileostomy reversal

Conditions: Inflammatory Bowel Diseases; Ileostomy

Summary: an ileostomy is a surgical opening established by bringing the end or a loop of the ileum to discharge directly outside the body. this is typically done when part or the entire colon is removed because of ibd, cancer, or familial adenomatous polyposis. reversal of this procedure, an ileostomy closure, may be done if possible. ileostomy closure involves reconnecting the ileum to the remaining colon, allowing normal bowel movements again. this study will look at the outcomes of these surgeries in patients who were seen and operated on by the investigators.

this study focused on outcomes and complications after ileostomy closure. an ileostomy is a surgical opening established by bringing the end or a loop of the ileum to discharge directly outside the body. this is typically done when part or the entire colon is removed because of ibd, cancer, or familial adenomatous polyposis. reversal of this procedure, an ileostomy closure, may be done if possible to reconnect the ileum to the remaining colon and allow normal bowel movements again. this study looked at the outcomes for these surgeries in patients who were seen and operated on by the investigators. patients were identified from the files and schedules of the investigators, and epic was used to collect the information needed to determine perioperative clinical characteristics and post-operative outcomes. this data was kept in a secure electronic database, with identifiers removed as soon as all of the data was collected for a patient.

Eligibility criteria:
inclusion criteria: * ileostomy closure procedure exclusion criteria: * none

Keywords: inflammatory bowel disease ileostomy ileostomy reversal stoma reversal
identifying genetic causes of ic/bps

Conditions: Interstitial Cystitis; Bladder Pain Syndrome

Summary: interstitial cystitis (ic), also called bladder pain syndrome (bps) is a common condition with no known cause or cure. twin studies and family accounts have suggested that the condition may be genetic or passed down (inherited) from one generation to another. in this study, we are collecting genetic material via blood or saliva and medical information from families in north america in an attempt to identify genetic factors that may cause ic/bps. we are enrolling inviduals with ic/bps and their family members (family members with and without ic like symptoms). travel to boston not required.

we are trying to identify a genetic cause of interstitial cystitis (ic)/bladder pain syndrome (bps). we are looking to enroll individuals with a clinical diagnosis of ic/bps and their family member. we are attempting to determine if there is a connection between symptoms of ic/pbs and changes in specific genes or a pathway of connected genes. we will use several genetic technologies including but not limited to; linkage analysis, genome sequencing, rnaseq and candidate gene studies to try to identify the cause of ic/bps. once we identify the cause of ic/bps we will be able to identify and design more effective treatments for affected individuals. we are looking for families with ic/bps symptoms to give a dna sample (from blood/saliva), urine samples, and answer several questionnaires. travel to boston not necessary.

Eligibility criteria:
inclusion criteria: * diagnosis of ic/bps * males and females of any age * urinary frequency - more than 1x/hour, and/or * dysuria, and/or * pelvic, suprapubic, or abdominal pain - for 3 months or longer * nocturia * normal urinary stream (by history) * no evidence of active bacterial uti (no pyuria \& negative urinary culture for last 3 months) * first degree relative of someone with above symptoms exclusion criteria: * major structural/anatomical urinary tract abnormalities by ultrasound * underlying inborn conditions affecting the urinary tract * surgery/chemotherapy affected pelvic area * gi or gu cancers * severe constipation in children only

Keywords: pelvic pain urinary frequency painful bladder urinary urgency
comparison between different ventilator hyperinflation maneuvers

Conditions: Infections, Respiratory; Ventilator Associated Pneumonia

Summary: the hyperinflation ventilator was performed in different modalities and ventilatory adjustments, with total pressure of 40cmh2o. the inspiratory volume, inspiratory time, mean airway pressure, inspiratory and expiratory flow, and bias flow were evaluated.

purpose: to compare different ways of applying ventilator hyperinflation. methods: a randomized crossover clinical trial was performed with 30 patients (66.5 ± 17.3 years) with hypersecretion. the ventilator hyperinflation was performed in five ventilatory modalities for five minutes, with an interval of 2 hours, the order being determined by randomization: controlled ventilation at volume (vcv) with constant flow of 20 (vcv20) lpm and 40 lpm (vcv40), controlled ventilation pressure ventilation (pcv), controlled pressure ventilation associated with inspiratory time adjustment (pcv + tins) and support pressure ventilation (psv). in vcv mode, the volume was increased every 50ml, until reaching a maximum pressure of 40cmh2o. in the pressure controlled modes, the inspiratory pressure was increased every 5 cmh2o until the total pressure reached 40 cmh2o. the inspiratory time was adjusted so that the inspiratory flow reached the baseline. the following variables were evaluated: tidal volume, inspiratory time (tins), mean airway pressure (pmean), peak inspiratory flow (pifr) and expiratory flow (pefr), pifr / pefr and bias flow (pefr-pifr).

Eligibility criteria:
inclusion criteria: * pulmonary infection * mechanically ventilated for more than 96 hours through pressure-assisted ventilation (psv) or pressure-controlled ventilation (pcv) * static compliance between 30 and 70 ml/cmh2o * peep between 5 and 8 cmh2o. exclusion criteria: * hemodynamic instability * non-drained pleural effusion or pneumothorax * intracranial hypertension * bronchospasm * adult respiratory distress syndrome (ards) * decompensated congestive heart failure

Keywords: ventilator hyperinflation physical therapy mechanical ventilation
fangshan / family-based ischemic stroke study in china

Conditions: Stroke

Summary: the exact etiology of ischemic stroke remains unclear, because multiple genetic predispositions and environmental risk factors may be involved, and their interactions dictate the complexity. family-based studies provide unique features in design because of their robustness to population admixture and stratification. the fangshan / family-based ischemic stroke study in china (fissic) program aims to conduct a genetic pedigree study of ischemic stroke in rural communities of china.

the fissic program is a community-based and hospital-centered genetic epidemiological study of ischemic stroke. the study design has two components: first, a family-based study of ischemic stroke pedigrees, including probands, their siblings, and their parents; second, the traditional matched case-control study of ischemic stroke cases and their unaffected spouses. cases with confirmed ischemic stroke are included as probands; after their informed consent is obtained, their parents, siblings, and unaffected spouses are recruited and screened by using the proband-initiated contact method. stroke status is verified at the central hospital, and the index stroke for each case is subtyped by medical records. baseline clinical and demographic data are collected by questionnaire, and longitudinal follow-up visits are scheduled. blood samples are collected from all enrolled participants through the three-tier prevention and health care network (village, township and county level) in the study area. the samples are sent to the central laboratory for processing, testing, and genotyping. the genotype data are then merged with the clinical, environmental, and follow-up data for analysis. comprehensive statistical methods are applied to both family-based and case-control data to ascertain potential complex genetic and environmental factors and their interactions.

Eligibility criteria:
inclusion criteria: * diagnosis of at least one ischemic stroke confirmed by the study neurologist on the basis of history, medical records, and head imaging by ct or mri; * at least 18 years old by the time of enrolment in the study; * at least one full sibling or parent alive in areas nearby; * written informed consent by the patient or surrogate. exclusion criteria: * diagnosis of transient ischemic attack (tia) only; * diagnosis of vasospasm after subarachnoid hemorrhage; * diagnosis of some mendelian disorders: cadasil, fabry disease, melas, or sickle cell anaemia; * diagnosis of iatrogenic ischemic stroke associated with a surgical / interventional procedure such as coronary artery bypass grafting, carotid endarterectomy, or heart valve surgery; * diagnosis of ischemic stroke associated with autoimmune condition or endocarditis.

Keywords: siblings